Caraco Pharmaceutical Laboratories Ltd., a subsidiary of Sun Pharma has launched a generic version of Sanofi-Aventis' cancer treatment Eloxatin.

It is launching the 50 milligram and 100-milligram generic doses of the drug after the FDA approved Sun Pharma's application. Oxaliplatin injections, the generic name for Eloxatin, have annual sales of about $1.3 billion in the U.S.